{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:49:54Z","timestamp":1777312194569,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000222","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000222","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010258","name":"Marfan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012453","name":"Providence Health Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.vph.2022.107112","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T12:34:13Z","timestamp":1664282053000},"page":"107112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties"],"prefix":"10.1016","volume":"147","author":[{"given":"Elodie","family":"Sauge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitri","family":"Pechkovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.D. Prasad","family":"Atmuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash Y.","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Cait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Donen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly M.","family":"McNagny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don D.","family":"Sin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco A.","family":"Ciufolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Bernatchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2022.107112_bb0005","article-title":"Physiology, renin angiotensin system","author":"Fountain","year":"2021","journal-title":"StatPearls"},{"issue":"1","key":"10.1016\/j.vph.2022.107112_bb0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI46215","article-title":"Angiotensin receptor blockade attenuates cigarette smoke - induced lung injury and rescues lung architecture in mice","volume":"122","author":"Podowski","year":"2012","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.vph.2022.107112_bb0015","first-page":"417","article-title":"Do angiotensin receptor blockers prevent Alzheimer\u2019s disease?","volume":"28","author":"Hajjar","year":"2022","journal-title":"Curr. Protoc. Cardiol."},{"issue":"12","key":"10.1016\/j.vph.2022.107112_bb0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2022.107112_bb0025","first-page":"506","article-title":"Angiotensin receptor blocker losartan inhibits tumor growth of colorectal cancer","volume":"20","author":"Hashemzehi","year":"2021","journal-title":"EXCLI J."},{"issue":"5","key":"10.1016\/j.vph.2022.107112_bb0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ana.22694","article-title":"Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) \/dy(2J) mouse","volume":"71","author":"Elbaz","year":"2012","journal-title":"Ann. Neurol."},{"issue":"5770","key":"10.1016\/j.vph.2022.107112_bb0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.[see comment]","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.vph.2022.107112_bb0040","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ajpath.2017.11.006","article-title":"Inhibition of Marfan syndrome aortic root dilation by losartan: role of angiotensin II receptor type 1\u2013independent activation of endothelial function","volume":"188","author":"Sellers","year":"2018","journal-title":"Am. J. Pathol."},{"issue":"22","key":"10.1016\/j.vph.2022.107112_bb0045","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJMoa1404731","article-title":"Atenolol versus losartan in children and young adults with Marfan\u2019s syndrome","volume":"371","author":"Lacro","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.vph.2022.107112_bb0050","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1097\/01.hjh.0000191906.03983.ee","article-title":"Blockade of angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects.[see comment]","volume":"23","author":"Demirci","year":"2005","journal-title":"J. Hypertens."},{"issue":"Suppl. 1","key":"10.1016\/j.vph.2022.107112_bb0055","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1038\/ncpcardio0806","article-title":"Reduction of proteinuria with angiotensin receptor blockers","volume":"5","author":"Galle","year":"2008","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"issue":"2","key":"10.1016\/j.vph.2022.107112_bb0060","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0022-3565(25)10800-8","article-title":"The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism","volume":"262","author":"Ohlstein","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.vph.2022.107112_bb0065","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/01.RES.0000014434.48463.35","article-title":"Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179","volume":"90","author":"Kr\u00e4mer","year":"2002","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.vph.2022.107112_bb0070","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2165\/00003088-200544080-00003","article-title":"Clinical pharmacokinetics of losartan","volume":"44","author":"Domenic","year":"2005","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.vph.2022.107112_bb0075","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/HYPERTENSIONAHA.109.138883","article-title":"Losartan metabolite EXP3179: an AT1-receptor-independent treatment strategy for patients with the metabolic syndrome","volume":"54","author":"GP","year":"2009","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.vph.2022.107112_bb0080","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/HYPERTENSIONAHA.109.138883","article-title":"Losartan metabolite EXP3179: an AT1-receptor-independent treatment strategy for patients with the metabolic syndrome","volume":"54","author":"GP","year":"2009","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.vph.2022.107112_bb0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2125.2012.04189.x","article-title":"Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants","volume":"74","author":"Mason","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.vph.2022.107112_bb0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.niox.2021.08.006","article-title":"Nitric oxide in the Marfan vasculature: friend or foe?","volume":"116","author":"Tehrani","year":"2021","journal-title":"Nitric Oxide"},{"issue":"5","key":"10.1016\/j.vph.2022.107112_bb0095","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1172\/JCI27100","article-title":"Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels","volume":"116","author":"Yu","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"19","key":"10.1016\/j.vph.2022.107112_bb0100","doi-asserted-by":"crossref","first-page":"12898","DOI":"10.1074\/jbc.M708226200","article-title":"Transforming growth factor \u03b21 induces \u03b1v\u03b23 integrin expression in human lung fibroblasts via a \u03b23 integrin-, c-Src-, and p38 MAPK-dependent pathway","volume":"283","author":"Pechkovsky","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.vph.2022.107112_bb0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/HYPERTENSIONAHA.112.203679","article-title":"Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein","volume":"61","author":"Herrera","year":"2013","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.vph.2022.107112_bb0110","first-page":"1","article-title":"Effect of aging and sex on cardiovascular structure and function in wildtype mice assessed with echocardiography","volume":"11","author":"Zhang","year":"2021","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.vph.2022.107112_bb0115","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1172\/JCI119426","article-title":"Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta: gender difference and effect of estrogen receptor gene disruption","volume":"99","author":"Rubanyi","year":"1997","journal-title":"J. Clin. Investig."},{"issue":"September","key":"10.1016\/j.vph.2022.107112_bb0120","first-page":"1","article-title":"Vascular aging in rodent models: contrasting mechanisms driving the female and male vascular senescence","volume":"2","author":"Barros","year":"2021","journal-title":"Front. Aging"},{"issue":"8","key":"10.1016\/j.vph.2022.107112_bb0125","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.ajpath.2019.05.003","article-title":"Sildenafil prevents Marfan-associated emphysema and early pulmonary artery dilation in mice","volume":"189","author":"White","year":"2019","journal-title":"Am. J. Pathol."},{"issue":"8","key":"10.1016\/j.vph.2022.107112_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220903","article-title":"Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B","volume":"14","author":"White","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2022.107112_bb0135","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1152\/ajpheart.00230.2009","article-title":"eNOS uncoupling and endothelial dysfunction in aged vessels","volume":"297","author":"Yang","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"4","key":"10.1016\/j.vph.2022.107112_bb0140","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00344.2002","article-title":"Recruitment of endothelial caveolae into mechanotransduction pathways by flow conditioning in vitro","volume":"285","author":"Rizzo","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"12","key":"10.1016\/j.vph.2022.107112_bb0150","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1161\/CIRCULATIONAHA.104.509760","article-title":"Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179","volume":"112","author":"Watanabe","year":"2005","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.vph.2022.107112_bb0155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/14017431.2012.754935","article-title":"Exercise training and losartan improve endothelial function in heart failure rats by different mechanisms","volume":"47","author":"Kemi","year":"2013","journal-title":"Scand. Cardiovasc. J."},{"issue":"3","key":"10.1016\/j.vph.2022.107112_bb0160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1254\/jphs.09308FP","article-title":"Losartan normalizes endothelium-derived hyperpolarizing factor-mediated relaxation by activating Ca2+ \u2212activated K+ channels in mesenteric artery from type 2 diabetic GK rat","volume":"112","author":"Matsumoto","year":"2010","journal-title":"J. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.vph.2022.107112_bb0165","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0022-3565(25)10800-8","article-title":"The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism","volume":"262","author":"Ohlstein","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.vph.2022.107112_bb0170","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2174\/138955712800959134","article-title":"Biased agonism of the angiotensin II type 1 receptor","volume":"12","author":"Godin","year":"2012","journal-title":"Mini-Rev. Med. Chem."},{"issue":"49","key":"10.1016\/j.vph.2022.107112_bb0175","doi-asserted-by":"crossref","first-page":"29127","DOI":"10.1074\/jbc.M115.689000","article-title":"Structural basis for ligand recognition and functional selectivity at angiotensin receptor","volume":"290","author":"Zhang","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.vph.2022.107112_bb0180","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1748-1716.2010.02127.x","article-title":"The effects of acute and chronic exercise on the vasculature","volume":"199","author":"Whyte","year":"2010","journal-title":"Acta Physiol."},{"issue":"9","key":"10.1016\/j.vph.2022.107112_bb0185","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1172\/JCI44778","article-title":"A noninhibitory mutant of the caveolin-1 scaffolding domain enhances eNOS-derived NO synthesis and vasodilation in mice","volume":"121","author":"Bernatchez","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.vph.2022.107112_bb0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.niox.2021.08.006","article-title":"Nitric oxide in the Marfan vasculature: friend or foe?","volume":"116","author":"Tehrani","year":"2021","journal-title":"Nitric Oxide"},{"issue":"7","key":"10.1016\/j.vph.2022.107112_bb0195","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/01.RES.0000014434.48463.35","article-title":"Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179","volume":"90","author":"Kr\u00e4mer","year":"2002","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.vph.2022.107112_bb0200","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/HYPERTENSIONAHA.109.129353","article-title":"Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension","volume":"54","author":"Fortu\u00f1o","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2022.107112_bb0205","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/01.HYP.0000196946.79674.8b","article-title":"Regulation of peroxisome proliferator - activated receptor \u03b3 activity by losartan metabolites","volume":"47, no. 3 II","author":"Schupp","year":"2006","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.vph.2022.107112_bb0210","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1021\/jm00112a031","article-title":"Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(Biphenylylmethyl)imidazoles as potent, orally active Antihypertensives","volume":"34","author":"Carini","year":"1991","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.vph.2022.107112_bb0215","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/01.HYP.19.3.255","article-title":"Effects of renin-angiotensin system blockade in guinea pigs","volume":"19","author":"Veniant","year":"1992","journal-title":"Hypertension"},{"issue":"12 Pt 2","key":"10.1016\/j.vph.2022.107112_bb0220","first-page":"1670","article-title":"Effects of chronic treatment with losartan on blood pressure, endothelin-like immunoreactivity and nitric oxide in normotensive rats","volume":"13","author":"Sacerdote","year":"1995","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.vph.2022.107112_bb0225","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/CIRCGENETICS.115.001040","article-title":"Potential phenotype-genotype correlation in Marfan syndrome: when less is more?","volume":"8","author":"Dietz","year":"2015","journal-title":"Circ. Cardiovasc. Genet."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189122001616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189122001616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:20:56Z","timestamp":1761528056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189122001616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":44,"alternative-id":["S1537189122001616"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2022.107112","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2022.107112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107112"}}